Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innoviva, Inc. - Common Stock
(NQ:
INVA
)
17.65
-0.13 (-0.73%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innoviva, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
June 06, 2023
From
Innoviva, Inc.
Via
Business Wire
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
May 24, 2023
Via
Benzinga
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 23, 2023
From
Innoviva, Inc.
Via
Business Wire
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
May 16, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
May 15, 2023
Via
Benzinga
5 Value Stocks In The Healthcare Sector
May 08, 2023
Via
Benzinga
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
April 18, 2023
Via
Benzinga
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
May 11, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Announces Retirement of Board Chairman
April 28, 2023
From
Innoviva, Inc.
Via
Business Wire
What 4 Analyst Ratings Have To Say About Innoviva
March 03, 2023
Via
Benzinga
Innoviva Earnings Perspective: Return On Capital Employed
December 19, 2022
Via
Benzinga
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
April 18, 2023
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs
Via
Benzinga
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Stock Trading Halted Today
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
March 13, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
February 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Four Undervalued Healthcare Stocks for 2023
January 06, 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Via
MarketBeat
Exposures
COVID-19
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
November 30, 2022
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 09, 2022
From
Innoviva, Inc.
Via
Business Wire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
October 19, 2022
--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints
From
Entasis Therapeutics Holdings Inc.
Via
GlobeNewswire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
October 12, 2022
Six abstracts selected for presentation, including three oral presentations
From
Entasis Therapeutics Holdings Inc.
Via
GlobeNewswire
A Look Into Healthcare Sector Value Stocks
October 03, 2022
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...
Via
Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
September 19, 2022
Via
Benzinga
5 Value Stocks In The Healthcare Sector
September 19, 2022
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 08, 2022
From
Innoviva, Inc.
Via
Business Wire
3 No-Brainer Stocks Under $10 to Buy for September
September 02, 2022
Cash-rich investors have the flexibility to buy no-brainer penny stocks to boost overall returns in a risk-adverse environment.
Via
InvestorPlace
Innoviva Completes Acquisition of La Jolla Pharmaceutical
August 22, 2022
From
Innoviva, Inc.
Via
Business Wire
Innoviva's Return On Capital Employed Overview
August 01, 2022
Pulled from Benzinga Pro data, Innoviva (NASDAQ:INVA) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 28, 2022
On Thursday, 108 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.